This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Cantor Fitzgerald in Signal Genetics Merger

November 23, 2016

NEW YORKCovington is advising Cantor Fitzgerald as financial advisor to Signal Genetics in connection with Signal’s merger transaction with miRagen Therapeutics.

Signal is a commercial stage, molecular diagnostic company that provides innovative diagnostic services that help physicians make better-informed decisions concerning the care of cancer patients. miRagen is a clinical stage biopharmaceutical company focused on the discovery and development of innovative microRNA-targeting therapies for disease.  

The Covington team consists of partner Jack Bodner, associate Allison Schiffman, and law clerk Ian Murray.

 

Share this article: